Laurie Toich, Assistant Editor

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Accounting for potential drug resistance improve the treatment of cancer.

Top news of the day from across the health care landscape.

Taurine may increase the remyelination effects of multiple sclerosis treatments.

Two-thirds of young women experienced at least 1 missed opportunity to receive the human papilloma virus vaccine.

Physically fit patients with coronary artery disease were nearly half as likely to die from cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Nilotinib (Tasigna) label includes information for patients with chronic myeloid leukemia who may stop treatment after achieving remission.

GammaPod system can accurately deliver radiation therapy to breast tumors.

The most popular articles of the year from The American Journal of Pharmacy Benefits.

A look back at the top articles of the year on Specialty Pharmacy Times.

The list price for 768 drugs commonly used by seniors increased by 6.4% in 2015

Polatuzumab vedotin plus bendamustine and rituximab increased complete response rates to 40% among patients with diffuse large B-cell lymphoma.

The most read FDA approval articles on The American Journal of Pharmacy Benefits.

A look at the most read drug approval articles of 2017 covered by Specialty Pharmacy Times.

Immunotherapy may reverse type 1 diabetes.

Cigarette smoking played a role in 19% of cancers and 29% of cancer-related deaths in 2014.

A look at the most popular videos on The American Journal of Pharmacy Benefits over the past year.

A look back at the debate around direct and indirect remuneration fees in 2017.

Enzymes that protect the immune system may malfunction and provoke cancer-related mutations.

A look at the most-read pharmacy benefit manager articles published on The American Journal of Pharmacy Benefits in 2017.

A review of the most popular video interviews on Specialty Pharmacy Times.

Pembrolizumab plus trastuzumab may overcome drug-resistance among patients with advanced HER2+ breast cancer.

The market for disease-modifying multiple sclerosis drugs is projected to reach $25.3 billion by 2026, according to a new report.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Paclitaxel plus nintedanib overcomes chemotherapy-resistance in endometrial cancer.

Inhibiting a protein kinase may improve the efficacy of radiation in glioblastoma.